OTCMKTS:CVSI CV Sciences (CVSI) Stock Price, News & Analysis $0.04 +0.00 (+3.95%) As of 08/22/2025 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About CV Sciences Stock (OTCMKTS:CVSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CV Sciences alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.02▼$0.05Volume30,120 shsAverage Volume157,079 shsMarket Capitalization$7.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. Read More CV Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreCVSI MarketRank™: CV Sciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CV Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCV Sciences has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCV Sciences does not currently pay a dividend.Dividend GrowthCV Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of CV Sciences has been sold short.Short Interest Ratio / Days to CoverCV Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CV Sciences has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News SentimentN/A News SentimentCV Sciences has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for CV Sciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for CVSI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added CV Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CV Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of CV Sciences is held by insiders.Read more about CV Sciences' insider trading history. Receive CVSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CVSI Stock News HeadlinesCV Sciences, Inc. (CVSI) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comCV Sciences Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 24 at 2:00 AM | Brownstone Research (Ad)CV Sciences Reports Improved Margins and Positive EBITDAAugust 14, 2025 | msn.comCV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025 | CVSI Stock NewsAugust 8, 2025 | gurufocus.comCV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3 | CVSI Stock NewsJune 23, 2025 | gurufocus.comQ1 2025 CV Sciences Inc Earnings CallMay 16, 2025 | uk.finance.yahoo.comCV Sciences targets cost efficiency gains and product diversification with in-source manufacturing and non-cannabinoid launchesMay 15, 2025 | msn.comSee More Headlines CVSI Stock Analysis - Frequently Asked Questions How have CVSI shares performed this year? CV Sciences' stock was trading at $0.0338 on January 1st, 2025. Since then, CVSI shares have increased by 16.9% and is now trading at $0.0395. How were CV Sciences' earnings last quarter? CV Sciences, Inc. (OTCMKTS:CVSI) posted its quarterly earnings results on Thursday, August, 12th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $5.13 million for the quarter, compared to analysts' expectations of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 80.82% and a negative net margin of 10.36%. How do I buy shares of CV Sciences? Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CV Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), KUSHCO (KSHB), NVIDIA (NVDA) and Organigram Global (OGI). Company Calendar Last Earnings8/12/2021Today8/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CVSI Previous SymbolNASDAQ:CVSI CIK1510964 Webwww.cvsciences.com Phone(866) 290-2157Fax619-876-4321Employees70Year Founded2016Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.39 million Net Margins-10.36% Pretax Margin-10.41% Return on Equity-80.82% Return on Assets-19.38% Debt Debt-to-Equity Ratio0.12 Current Ratio1.04 Quick Ratio0.30 Sales & Book Value Annual Sales$15.70 million Price / Sales0.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book3.95Miscellaneous Outstanding Shares184,790,000Free Float182,392,000Market Cap$7.30 million OptionableNot Optionable Beta0.61 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:CVSI) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CV Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CV Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.